Cargando…

Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study

Purpose: To conduct a population-based study to determine whether the use of GnRH agonist and antiandrogens are associated with an increased risk of cardio-cerebrovascular disease (CCVD) in Asian patients with prostate cancer using the National Health Insurance Service-Elderly Cohort Database (NHIS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seong, Jong-Mi, Shin, Dongho, Sung, Jae Woo, Cho, Shinjay, Yang, Jonghyup, Kang, Sungmin, Moon, Hyong Woo, Lee, Kyu Won, Ha, U-Syn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196249/ https://www.ncbi.nlm.nih.gov/pubmed/32368283 http://dx.doi.org/10.7150/jca.38237

Ejemplares similares

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study
por: Shim, Myungsun, et al.
Publicado: (2020)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case
por: Huang, Tsung-Yi, et al.
Publicado: (2013)

Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients
por: Kim, Tae-Jung, et al.
Publicado: (2019)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Effects of human growth hormone on gonadotropin-releasing hormone neurons in mice
por: Bhattarai, Janardhan P., et al.
Publicado: (2010)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
por: Jung, Mo Kyung, et al.
Publicado: (2014)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

The efficacy of gonadotropin-releasing hormone agonist treatment before hysteroscopic myomectomy for large-sized submucosal leiomyoma
por: Park, Mia, et al.
Publicado: (2022)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
por: Scaruffi, Paola, et al.
Publicado: (2019)

Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty
por: Lee, Hae Sang, et al.
Publicado: (2018)

Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment
por: Park, Chan Woo, et al.
Publicado: (2016)

Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
por: Lee, Juhyeon, et al.
Publicado: (2023)

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist
por: duPont, Nefertiti Chianti, et al.
Publicado: (2010)

Increased Risk of Pneumonia in Patients Receiving Gonadotropin-Releasing Hormone Agonists for Prostate Cancer
por: Chung, Shiu-Dong, et al.
Publicado: (2014)

Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment
por: Gül, Ülkü, et al.
Publicado: (2016)

Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
por: Mohamad, Nur-Vaizura, et al.
Publicado: (2018)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017)

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
por: Yoon, Jong Wan, et al.
Publicado: (2017)

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis
por: Gocho, Naoki, et al.
Publicado: (2018)

Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles
por: Türkgeldi, Engin, et al.
Publicado: (2015)

Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin-releasing hormone agonist
por: Ma, Nieying, et al.
Publicado: (2020)

Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
por: Marin, Loris, et al.
Publicado: (2022)

The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study
por: Shim, Myungsun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rem4fl54vus6su8trhiatk8gr4